Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Immune-related progression free survival (irPFS) rate at 20 weeks in patients with MSI positive and negative colorectal adenocarcinoma using immune related response criteria (irRC)
4 years
No
Dung Le, MD
Principal Investigator
Sidney Kimmel Comprehensive Cancer Center
United States: Food and Drug Administration
J1365
NCT01876511
July 2013
Name | Location |
---|---|
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore, Maryland 21231-2410 |